Demographic, clinical characteristics and medical therapy of the study population
| Angiography (n=13) | PCI (n=23) | p Value | |
|---|---|---|---|
| Demographics | |||
| Age, years | 63±2.7 | 61±2.3 | 0.51 |
| Male gender, n (%) | 10 (77) | 19 (83) | 0.68 |
| Body mass index, kg/m2 | 27.5±1.8 | 28.9±0.9 | 0.51 |
| Clinical characteristics | |||
| Smoking status, n (%) | |||
| Current smoker | 4 (31) | 2 (9) | 0.11 |
| Ex smoker | 6 (46) | 11 (48) | 0.71 |
| Non smoker | 3 (23) | 10 (44) | 0.22 |
| Hypertensive, n (%) | 6 (46) | 19 (83) | 0.02 |
| Diabetic, n (%) | 2 (15) | 3 (13) | 0.85 |
| Hyperlipidaemia, n (%) | 8 (62) | 17 (74) | 0.32 |
| Family history of CAD, n (%) | 5 (39) | 16 (70) | 0.07 |
| Previous MI, n (%) | 5 (39) | 13 (57) | 0.30 |
| CABG, n (%) | 1 (8) | 2 (9) | 0.92 |
| PCI, n (%) | 2 (15) | 10 (44) | 0.09 |
| PVD, n (%) | 2 (15) | 3 (13) | 0.85 |
| LVSD, n (%) | 3 (23) | 6 (26) | 0.84 |
| Stroke, n (%) | 1 (8) | 1 (4) | 0.67 |
| Creatinine, mg/dL | 103±4 | 98±3 | 0.34 |
| Cholesterol, mg/dL | 4.3±0.3 | 4.4±0.2 | 0.95 |
| Medical therapy | |||
| Aspirin, n (%) | 9 (77) | 23 (100) | 0.05 |
| Clopidogrel, n (%) | 4 (31) | 18 (78) | 0.01 |
| β-blocker, n (%) | 7 (54) | 17 (74) | 0.22 |
| Statin, n (%) | 10 (77) | 22 (96) | 0.09 |
| ACE inhibitor, n (%) | 4 (31) | 14 (61) | 0.08 |
| ARB, n (%) | 1 (8) | 1 (4) | 0.67 |
Continuous variables are expressed as the mean±SE or median (IQR) with statistical comparisons between patients with ACS and suspected stable angina performed using the Student t test or Mann–Whitney, where appropriate. Categorical variables are expressed as the absolute number of cases and the group proportion (%) with statistical comparisons performed using a χ2 test.
ARB, angiotensin receptor blocker; CABG, coronary artery bypass; CAD, coronary artery disease; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.